Shelia Violette (Q32)

For a post-Soliris world, At­las-backed Q32 Bio out­lines $46M next-gen com­ple­ment play

Long be­fore Alex­ion kin­dled a re­nais­sance of com­ple­ment ther­a­peu­tics with the in­tro­duc­tion of the first an­ti-C5 an­ti­body, Mike Holers — a long­time pro­fes­sor at the Uni­ver­si­ty of Col­orado School of Med­i­cine — be­came fas­ci­nat­ed with the host de­fense sys­tem as he com­plet­ed his rheuma­tol­ogy train­ing. As Soliris be­gins to fade and fol­low-on, ri­vals and even gener­ics catch up to the stan­dard bear­er. Holers is de­but­ing a next-gen­er­a­tion ap­proach he’s been re­fin­ing with At­las Ven­ture over the last two years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.